218 related articles for article (PubMed ID: 28830887)
1. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
Bobrowicz M; Dwojak M; Pyrzynska B; Stachura J; Muchowicz A; Berthel E; Dalla-Venezia N; Kozikowski M; Siernicka M; Miazek N; Zapala P; Domagala A; Bojarczuk K; Malenda A; Barankiewicz J; Graczyk-Jarzynka A; Zagozdzon A; Gabrysiak M; Diaz JJ; Karp M; Lech-Maranda E; Firczuk M; Giannopoulos K; Efremov DG; Laurenti L; Baatout D; Frenzel L; Malinowska A; Slabicki M; Zenz T; Zerrouqi A; Golab J; Winiarska M
Blood; 2017 Oct; 130(14):1628-1638. PubMed ID: 28830887
[TBL] [Abstract][Full Text] [Related]
2. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
3. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
5. The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.
Scialdone A; Hasni MS; Damm JK; Lennartsson A; Gullberg U; Drott K
Oncotarget; 2017 Jun; 8(23):37409-37422. PubMed ID: 28445158
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab.
Felberg A; Taszner M; Urban A; Majeranowski A; Jaskuła K; Jurkiewicz A; Stasiłojć G; Blom AM; Zaucha JM; Okrój M
Front Immunol; 2020; 11():584509. PubMed ID: 33329558
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.
Bhatt S; Parvin S; Zhang Y; Cho HM; Kunkalla K; Vega F; Timmerman JM; Shin SU; Rosenblatt JD; Lossos IS
Blood; 2017 Apr; 129(16):2246-2256. PubMed ID: 28137826
[TBL] [Abstract][Full Text] [Related]
8. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
[TBL] [Abstract][Full Text] [Related]
10. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
[TBL] [Abstract][Full Text] [Related]
11. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.
Pickartz T; Ringel F; Wedde M; Renz H; Klein A; von Neuhoff N; Dreger P; Kreuzer KA; Schmidt CA; Srock S; Schoeler D; Schriever F
Exp Hematol; 2001 Dec; 29(12):1410-6. PubMed ID: 11750099
[TBL] [Abstract][Full Text] [Related]
12. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
13. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
[TBL] [Abstract][Full Text] [Related]
14. Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
Skarzynski M; Niemann CU; Lee YS; Martyr S; Maric I; Salem D; Stetler-Stevenson M; Marti GE; Calvo KR; Yuan C; Valdez J; Soto S; Farooqui MZ; Herman SE; Wiestner A
Clin Cancer Res; 2016 Jan; 22(1):86-95. PubMed ID: 26283682
[TBL] [Abstract][Full Text] [Related]
15. Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells.
Xu Y; Li S; Wang Y; Liu J; Mao X; Xing H; Tian Z; Tang K; Liao X; Rao Q; Xiong D; Wang M; Wang J
Hum Gene Ther; 2019 Apr; 30(4):497-510. PubMed ID: 30381966
[TBL] [Abstract][Full Text] [Related]
16. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
Teeling JL; French RR; Cragg MS; van den Brakel J; Pluyter M; Huang H; Chan C; Parren PW; Hack CE; Dechant M; Valerius T; van de Winkel JG; Glennie MJ
Blood; 2004 Sep; 104(6):1793-800. PubMed ID: 15172969
[TBL] [Abstract][Full Text] [Related]
17. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.
Jilani I; O'Brien S; Manshuri T; Thomas DA; Thomazy VA; Imam M; Naeem S; Verstovsek S; Kantarjian H; Giles F; Keating M; Albitar M
Blood; 2003 Nov; 102(10):3514-20. PubMed ID: 12893761
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms.
Wojciechowski W; Li H; Marshall S; Dell'Agnola C; Espinoza-Delgado I
J Immunol; 2005 Jun; 174(12):7859-68. PubMed ID: 15944291
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 antibody treatment of non-Hodgkin lymphomas.
Engelhard M
Clin Immunol; 2016 Nov; 172():101-104. PubMed ID: 27531574
[TBL] [Abstract][Full Text] [Related]
20. BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.
Nishida M; Uematsu N; Kobayashi H; Matsunaga Y; Ishida S; Takata M; Niwa O; Padlan EA; Newman R
Int J Oncol; 2011 Feb; 38(2):335-44. PubMed ID: 21152859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]